Center for Medical Technology Policy, Baltimore, MD 21202, USA.
Centre for Public Health, Queen's University Belfast, Belfast, UK.
J Comp Eff Res. 2016 Mar;5(2):193-205. doi: 10.2217/cer-2015-0007. Epub 2016 Mar 1.
Policy makers have clearly indicated--through heavy investment in the Patient Centered Outcomes Research Institute--that reporting outcomes that are meaningful to patients is crucial for improvement in healthcare delivery and cost reduction. Better interpretation and generalizability of clinical research results that incorporate patient-centered outcomes research can be achieved by accelerating the development and uptake of core outcome sets (COS). COS provide a standardized minimum set of the outcomes that should be measured and reported in all clinical trials of a specific condition. The level of activity around COS has increased significantly over the past decade, with substantial progress in several clinical domains. However, there are many important clinical conditions for which high-quality COS have not been developed and there are limited resources and capacity with which to develop them. We believe that meaningful progress toward the goals behind the significant investments in patient-centered outcomes research and comparative effectiveness research will depend on a serious effort to address these issues.
政策制定者已明确表示——通过对患者为中心的结局研究机构大力投资——报告对患者有意义的结果对于改善医疗服务提供和降低成本至关重要。通过加速核心结局集（COS）的开发和采用，可以更好地解释和推广纳入患者为中心的结局研究的临床研究结果。COS 提供了一个标准化的最小结果集，应在特定疾病的所有临床试验中测量和报告。在过去十年中，COS 的活动水平显著增加，在几个临床领域取得了实质性进展。然而，仍有许多重要的临床病症尚未制定出高质量的 COS，并且开发这些病症的资源和能力有限。我们认为，要实现患者为中心的结局研究和比较效果研究的巨额投资背后的目标，就必须认真解决这些问题。
